Alfuzosin Hydrochloride Tablet, Extended Release
Product Images NDC 51655-432

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Alfuzosin Hydrochloride (NDC 51655-432). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Northwind Health Company, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Label (51655 432 52)

Label (51655 432 52)
Label for Alfuzosin Hydrochloride extended-release tablets, 10 mg strength, oral dosage form, containing 30 tablets. The label includes storage instructions, dosage note to see package insert, and manufacturer information indicating Northwind Pharmaceuticals. It also shows barcodes and NDC number 51655-432-52.*
FDA Label Image

Chemical-structure (Chemical Structure)

Chemical-structure (Chemical Structure)
Chemical structure of Alfuzosin Hydrochloride, showing its molecular framework including methoxy groups, amino group, and hydrochloride component.*
FDA Label Image

Figure-1 (Figure 1)

Figure-1 (Figure 1)
A line graph showing Alfuzosin plasma concentration (ng/mL) over 24 hours versus time (hours). Two curves compare plasma levels under fed and fasted conditions, with the fed condition showing higher peak concentrations around 8 hours and a decline thereafter, while the fasted condition has lower and more stable concentrations.*
FDA Label Image

Figure-2 (Figure 2)

Figure-2 (Figure 2)
A line graph showing the mean change from baseline in IPSS total symptom score over 84 days of treatment, comparing placebo (N=167) and alfuzosin hydrochloride extended-release tablets (N=170). The graph illustrates a greater reduction in symptom score with alfuzosin hydrochloride versus placebo, with statistical significance indicated (p < 0.001).*
FDA Label Image

Figure-3 (Figure 3)

Figure-3 (Figure 3)
A line graph comparing mean change from baseline in IPSS total symptom score over 84 days of treatment between placebo and Alfuzosin hydrochloride extended-release tablets. The x-axis represents days of treatment (0, 28, 56, 84) and the y-axis shows mean change values. The chart indicates a greater mean decrease in symptom score with Alfuzosin hydrochloride extended-release tablets compared to placebo, with statistical significance at day 84 (p < 0.01).*
FDA Label Image

Figure-4 (Figure 4)

Figure-4 (Figure 4)
A line graph showing mean change in IPSS Total Symptom Score over 84 days of treatment comparing Alfuzosin hydrochloride extended-release tablets (N=151) to placebo (N=150). The y-axis represents mean change, with Alfuzosin showing a greater decrease in score than placebo, especially notable at day 84.*
FDA Label Image

Figure-5 (Figure 5)

Figure-5 (Figure 5)
A line graph showing mean change from baseline in peak urine flow rate (mL/s) over 84 days of treatment. It compares placebo and Alfuzosin hydrochloride extended-release tablets in two groups (N=167 and N=170). Alfuzosin shows a sustained increase in flow rate compared to placebo with statistical significance indicated at day 84 (p < 0.001).*
FDA Label Image

Figure-6 (Figure 6)

Figure-6 (Figure 6)
A line chart illustrating mean change from baseline in peak urine flow rate (mL/s) over 84 days of treatment. It compares placebo and Alfuzosin hydrochloride extended-release tablets, showing mean change on the vertical axis and days of treatment on the horizontal axis. Statistical significance is indicated at day 84.*
FDA Label Image

Figure-7 (Figure 7)

Figure-7 (Figure 7)
Line graph showing mean change from baseline in peak urine flow rate (mL/s) over days of treatment (0, 14, 28, 56, 84) for Alfuzosin hydrochloride extended-release tablets and placebo. The graph compares the two groups (N=151 for Alfuzosin, N=150 for placebo) with Alfuzosin demonstrating a higher mean increase, although labeled NS indicating no statistically significant difference (p > 0.05).*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.